180 Life Soars 206% on $1.73B Surge to 39th Busiest Stock Amid Institutional Frenzy and Trial Hopes

On August 12, 2025, 180 Life (ATNF) surged 206.59% with a trading volume of $1.73 billion, marking a 6,367.06% increase in volume compared to the previous day and ranking 39th in market activity. The biotech firm’s stock saw heightened institutional interest amid speculation around potential partnerships and clinical trial updates. Analysts noted the spike was driven by renewed investor confidence in its pipeline advancements and regulatory filings.

Recent filings indicated progress in key therapeutic areas, including oncology and rare diseases, with preliminary data from Phase II trials attracting attention. Institutional investors have been incrementally building positions in the stock over the past quarter, reflecting its strategic positioning in the life sciences sector. Short-term momentum appears to be supported by a shift in market risk appetite and sector rotation into high-growth biotech names.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day resulted in a moderate return. The total profit from December 2021 to August 2025 was $2,940, with a maximum drawdown of $-1,960 during the same period. The strategy's average daily return was 0.24%, with a Sharpe ratio of 0.67 and a maximum Sharpe of 1.2 over the past four years.